Skip to content

Regulatory Effects and Neural Mechanisms of Hi-tACS on Adolescent Bipolar Depressive Disorder

Regulatory Effects and Neural Mechanisms of Hi-tACS on Adolescent Bipolar Depressive Disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109739
Enrollment
Unknown
Registered
2025-09-24
Start date
2025-07-18
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar depressive disorder

Interventions

Active stimulation group:Active stimulation

Sponsors

The Second People's Hospital of Guizhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 28 Years

Inclusion criteria

Inclusion criteria: 1. Age: 13-28 years old, right-handed; 2.Gender: No limit for men and women; 3.Meet DSM-V diagnostic criteria for bipolar disorder, currently in a depressed state (HAMD17>=7 points), and not in a manic or hypomanic state (YMRS<=5 points); 4.The treatment plan for psychiatric drugs is stable within 12 weeks before screening, and the types and dosage of psychiatric drugs used during the planned treatment period do not need to be adjusted (low-dose quetiapine fumarate is used as the basic drug, and the dose is <300mg/day); 5.Junior high school education level and above and sufficient to understand the content of neuropsychological tests.

Exclusion criteria

Exclusion criteria: 1.Intellectual retardation, severe physical disease, equipped with a pacemaker; 2.People with previous diagnosis of mental disorders associated with schizophrenia, schizoaffective mental disorder or other diseases; 3.Those who have abused psychoactive substances within 3 months; 4.Female patients during pregnancy or breastfeeding; 5.Currently (or the last 4 weeks) take more than 2 mg (or equivalent) of lorazepam or any dose of seizure medication every day; 6.Abnormal brain structure or any contraindications for MRI scanning were found through magnetic resonance examination; 7.In the past month, patients receiving MECT-free electroconvulsive (MECT) treatment.

Design outcomes

Primary

MeasureTime frame
Change from baseline in the Hamilton Depression Rating Scale total score;

Secondary

MeasureTime frame
Response rate; Change from baseline in the Young Mania Rating Scale total score;Change in oxyhemoglobin concentration;Change in functional connectivity strength within or between brain networks;

Countries

China

Contacts

Public ContactShu Yanping

The Second People's Hospital of Guizhou Province

doctor_sue@yeah.net+86 139 8540 2340

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026